Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III
06:26pm, Friday, 23'rd Sep 2022 Zacks Investment Research
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs
02:07pm, Friday, 23'rd Sep 2022 Zacks Investment Research
Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.
Novartis outlines plan to become a 'top-five player' in U.S. pharmaceuticals market
08:58am, Friday, 23'rd Sep 2022
Novartis AG NOVN, -0.84% on Thursday told investors that the Swiss drug maker plans to adopt a "U.S.-first mindset" in its bid to become a "top-five player" in the U.S. market by 2027. Novartis is one
Strength Seen in Lilly (LLY): Can Its 4.9% Jump Turn into More Strength?
06:57am, Friday, 23'rd Sep 2022 Zacks Investment Research
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the n
Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent
03:04pm, Thursday, 22'nd Sep 2022 Zacks Investment Research
Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.
Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent
12:48pm, Thursday, 22'nd Sep 2022
Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.
Reuters
CATL's 3rd Largest Customer After Tesla, Nio Cuts Reliance On Battery Giant In Bid For Diversification
XPeng Inc (NYSE: XPEV) has diversified its battery suppliers and does not count indu
7 Safe Havens All Investors Should Have Exposure to in 2022
07:00am, Thursday, 22'nd Sep 2022
Investors who have a high exposure to stocks in 2022 probably wish the year would end. Unless they raised their allocation in cash, their losses in the portfolio are mounting.
Novartis to prioritise U.S. market unfazed by drug pricing pushback
01:42am, Thursday, 22'nd Sep 2022
Swiss pharma giant Novartis said it would make growth in the United States its top geographic priority, even after laws were passed to rein in drug prices in the world's largest pharmaceutical market.
3 Highly Profitable Stocks That Are Super Cheap Right Now
12:45pm, Wednesday, 21'st Sep 2022 The Motley Fool
The bear market has gone overboard with these three stocks.
Wall Street Journal
Sam Bankman-Fried's FTX, Binance Reportedly In The Lead To Buy Voyager Digital's Assets
The assets of defunct cryptocurrency lender Voyager Digital Ltd (OTC: VYGVQ) have attra
Novartis to take U.S. drug patent case to Supreme Court
01:27am, Wednesday, 21'st Sep 2022
Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals cou
3 Stocks That Could Rocket on Biden's Cancer Moonshot
04:18pm, Tuesday, 20'th Sep 2022
The idea that anyone could have a problem with Joe Biden's cancer moonshot is unimaginable. After all, who hasn't had a friend or relative affected by cancer?
Novartis (NVS) Unit Posts Positive Results on Prolia Biosimilar
03:12pm, Tuesday, 20'th Sep 2022 Zacks Investment Research
Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.
Novartis (NVS) Unit Posts Positive Results on Prolia Biosimilar
12:48pm, Tuesday, 20'th Sep 2022
Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.
